Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology
Abstract
No abstract available
DAVID KLATZMANN : Connect in order to contact the contributor
https://www.hal.inserm.fr/inserm-01617417
Submitted on : Tuesday, November 15, 2022-3:37:03 PM
Last modification on : Tuesday, April 11, 2023-5:37:20 PM
Long-term archiving on: Thursday, February 16, 2023-8:11:49 PM